Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | The potential of differentiation therapies for AML

Stéphane de Botton • 5 Oct 2017
ESH 2017
Acute Myeloid Leukemia Enasidenib

Stéphane de Botton, MD, PhD of the Gustave Roussy Institute, Villejuif, France, discusses the efficiency of differentiation therapies for the elimination of acute myeloid leukemia at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH). Dr de Botton emphasizes the need to further improve results via the use of combination therapies, and describes how enasidenib can be combined with a wide variety of targeted drugs and other agents.

More from Stéphane de Botton

3:52
A Phase II study evaluating the safety and efficacy of olutasidenib in patients with R/R mIDH1 AML
Stéphane de Botton • 28 Nov 2022
6:53
The efficacy and toxicity of reduced venetoclax exposure in patients with treatment-naïve AML
Stéphane de Botton • 28 Nov 2022
2:15
Treatment strategies for patients with AML who possess a FLT3 mutation
Stéphane de Botton • 28 Nov 2022
4:19
Molecular characterization of patients in AGILE: azacitidine + ivosidenib or placebo in IDH1m AML
Stéphane de Botton • 28 Nov 2022

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals